U.S. Markets closed

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
39.00-0.40 (-1.02%)
At close: 4:00PM EDT
People also watch

Supernus Pharmaceuticals, Inc.

1550 East Gude Drive
Rockville, MD 20850
United States

IndustryDrugs - Generic
Full Time Employees363

Key Executives

Mr. Jack A. KhattarFounder, Chief Exec. Officer, Pres, Sec. and Director1.13MN/A56
Mr. Gregory S. Patrick M.E., M.B.A.Chief Financial Officer and VP504.75kN/A66
Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer and Sr. VP of Intellectual Property502.75kN/A60
Mr. Victor L. VaughnSr. VP of Sales and Marketing517.16kN/A59
Dr. Stefan K. F. Schwabe M.D., Ph.D.Chief Medical Officer and Exec. VP of R&D566.66kN/A65
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Corporate Governance

Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.